Leqembi Real-World LEADER Study validates the Real-World Performance New interim findings from the LEADER study, a three-year retrospective analysis of Leqembi (lecanemab), indicate sustained therapeutic efficacy in a real-world clinical setting. Analyzing data from 432 patients across 13 U.S. clinical sites, the study reports that 82.5% of individuals with early-stage Alzheimer’s disease (AD) experienced disease stabilization or cognitive improvement after an average treatme

Merck has secured FDA approval for LIPFENDRA (enlicitide) 20 mg tablets, establishing the first oral PCSK9 inhibitor available for the management of hypercholesterolemia. Approved as an adjunct to diet and exercise, the macrocyclic peptide is indicated for adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). Also read: CMS Proposes Major Medicare Overhaul: Shifting Toward Accountable Care and Value-Based Payments The therap